HOME > TOP STORIES

TOP STORIES

BUSINESS Ethical Drug Sales Up 2.5% in October: Crecon Report

December 10, 2013
REGULATORY FPMAJ OKs Concession Plan on Key Premium; Bill Payers Stick to Opposition

December 9, 2013
BUSINESS “Objective Accomplished,” Daiichi Sankyo to Terminate Ranmark Copromotion with AZ at Year-End

December 9, 2013
BUSINESS Generics Showed Strong Growth in 1st Half of FY2013 Despite Lack of New Measures to Promote Their Use

December 6, 2013
BUSINESS Takeda Offered 600 M. Yen in Grants to Kyoto University Involved in CASE-J Study, Where Ex-Employee Affiliated

December 5, 2013
REGULATORY Would Proposed New Rule for Repricing Long-Listed Drugs Create Winners and Losers? Bill Payers Opposed, Industry Watching Closely

December 5, 2013
BUSINESS Ono Joins SGLT-2 Inhibitor Battle via Copromotion Deal with AstraZeneca

December 4, 2013
BUSINESS Reimbursement Listing of Ipragliflozin Expected in April; 4 Rival SGLT-2 Inhibitors Seen to Follow Suit 1 Month Later

December 3, 2013
BUSINESS Merck to Shed 200 Jobs in Japan by 2015

December 3, 2013
BUSINESS GSK Exec Tapped as Takeda’s Next President, 1st Non-Japanese to Lead Japan Juggernaut

December 2, 2013
BUSINESS AnGes MG to Resume Collategene Development for Critical Limb Ischemia Treatment: President Yamada

November 29, 2013
REGULATORY MHLW Proposes to “Institutionalize” New Drug Premium; Equivocal Wording Draws Fire at CSIMC

November 28, 2013
BUSINESS President Hasegawa of Takeda Confident About Achieving Targets in Midterm Growth Strategy; Company to Appoint CIO

November 28, 2013
BUSINESS Azilva Tops Physician “Mind Share” Ranking in GP, HP Markets in October: New Survey

November 27, 2013
BUSINESS Eisai to Take Over Marketing Rights for Gliadel from Nobelpharma

November 27, 2013
ACADEMIA All Clinical Studies Should Follow GCP Requirements: Ex-AZ Chairman Kato

November 26, 2013
BUSINESS Farmorubicin Approved for Additional Dosage and Administration for Hepatic Cancer: Pfizer Japan

November 26, 2013
BUSINESS AZ Aims to Maintain Presence in Oncology Field Via Partnerships until Launch of New Drugs

November 25, 2013
BUSINESS Takeda Deploys Cardiovascular, Diabetes Sales Reps for Comprehensive Detailing Activities for Lifestyle Diseases

November 22, 2013
BUSINESS Japan Diovan Sales Down 15.7% in July-September: IMS

November 22, 2013

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch

By Ken Yoshino

Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…